continued

3 downloads 0 Views 44KB Size Report
Oct 29, 2016 - Waltham, Massachusetts; 2Macrolide Therapeutics, Watertown, Massachusetts;. 3AstraZeneca, Waltham, Massachusetts; 4AstraZeneca ...
2246. Sulbactam Combined With the Novel β-lactamase Inhibitor ETX2514 for the Treatment of Multidrug-Resistant Acinetobacter baumannii Infections Sarah McLeod, PhD1; Adam Shapiro, PhD1; Samir Moussa, PhD1; Nicole Carter, MS1; Michele Johnstone, MS2; Robert McLaughlin, PhD3; Boudewijn Dejonge, PhD4; Ruben Tommasi, PhD1; John Mueller, PhD1; Alita Miller, PhD1; 1Entasis Therapeutics, Waltham, Massachusetts; 2Macrolide Therapeutics, Watertown, Massachusetts; 3 AstraZeneca, Waltham, Massachusetts; 4AstraZeneca Pharmaceuticals, Waltham, Massachusetts Session: 247. New Antibiotics in Development Saturday, October 29, 2016: 12:30 PM Background. Multidrug-resistant (MDR) Acinetobacter baumannii infections are of great concern due to high mortality rates and limited number of treatment options. β-lactamase (BL) expression, especially class D, is an important resistance mechanism in this organism. The novel BL inhibitor ETX2514 has potent activity against class A, C, and D serine BLs. The MIC90 of sulbactam (SUL) in the presence of ETX2514 is 4 mg/L against a large, globally diverse set of MDR A. baumannii clinical isolates from 2014. In this study, we investigate the mechanism of synergy of this combination alone or in the presence of imipenem (IPM) or meropenem (MEM), whose spectra of target inhibition vary across bacterial species Methods. MICs were performed according to CLSI guidelines. The frequency of resistance (FOR) to SUL/ETX2514 was determined in several clinical isolates of A. baumannii. Resistant mutants were analyzed by whole-genome sequencing. Morphological changes were examined by microscopy. PBP acylation rates were determined by competition with BOCILLIN FL in fluorescence polarization assays. Results. The MIC50 and MIC90 of relevant combinations against 598 contemporary isolates of A. baumannii are shown in the table.

Compound(s)

MIC50

MIC90

continued. Compound(s)

MIC50

MIC90

SUL IPM MEM SUL/ETX2514* IPM/ETX2514* IPM/SUL* IPM/SUL*/ETX2514* MEM/SUL*/ETX2514*

1 32 32 1 4 32 ≤0.03 ≤0.03

>32 >32 >32 4 16 >32 ≤0.03 4

*held constant at 4 mg/L

SUL-treated A. baumannii strains had elongated cell morphologies which became spherical when ETX2514 was added, a phenotype associated with PBP2 inhibition in Escherichia coli. The FOR to SUL/ETX2514 at 4 × MIC was 7.6 × 10–10. Resistance in A. baumannii mapped to residues S390T, S395F, or F548C in PBP3 or to mutations in transfer RNA synthetase genes (aspS and gltX). The latter are associated with resistance to PBP2 inhibitors in E. coli. Purified mutant PBP3 proteins had reduced affinity for SUL and variable affinity for IPM and MEM in BOCILLIN competition assays. Conclusion. Resistance mapping and morphological changes suggest that, in addition to BL inhibition, ETX2514 enhances antibacterial activity through PBP2 inhibition in A. baumannii. The remarkable synergy observed with the triple combination IMP/SUL/ETX2514 likely reflects superior antibacterial potency achieved through a combination of BL inhibition and expanded PBP inhibition. Disclosures. S. McLeod, Entasis Therapeutics: Employee, Salary; A. Shapiro, Entasis Therapeutics: Employee, Salary; S. Moussa, Entasis Therapeutics: Employee, Salary; N. Carter, Entasis Therapeutics: Employee, Salary; R. Tommasi, Entasis Therapeutics: Employee, Salary; Entasis Therapeutics: Employee, Salary; J. Mueller, Entasis Therapeutics: Employee and Shareholder, Salary; A. Miller, Entasis Therapeutics: Employee, Salary

Poster Abstracts



OFID 2016:3 (Suppl 1)



S599